TNBC: Metronomic Capecitabine Maintenance Improves Outcomes

Metronomic capecitabine maintenance after standard treatment has been shown to be a successful therapy for patients with triple-negative breast cancer (TNBC) in a recent study. Results of this study will be reported on later this week in the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program.Relapse and unfavorable outcomes are still issues among patients with TNBC. According to lead study author XI Wang, MD of the Department of Breast Oncology at Sun Yat-Sen University...
Continue reading

FDA Approves Nivolumab/Ipilimumab/Platinum-Doublet Chemotherapy: NSCLC

Nivolumab (Opdivo®, Bristol Myers Squibb) plus ipilimumab (Yervoy®, Bristol Myers Squibb) in combination with 2 cycles of platinum-doublet chemotherapy has been FDA approved for treatment-naive patients with metastatic or recurrent non-small cell lung cancer (NSCLC), with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations. Approval was based on the randomized, open-label trial CHECKMATE-9LA (NCT03215706). A total of 719 patients with met...
Continue reading

Brigatinib Approved for ALK-Positive Non-Small Cell Lung Cancer

For patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), the FDA has approved brigatinib (ALUNBRIG®, Takeda). In addition, the companion diagnostic for brigatinib, Vysis ALK Break Apart FISH Probe Kit (Abbott Molecular, Inc.) has also been approved. A next-generation ALK inhibitor, brigatinib works by targeting a broad range of ALK mutations.Approval was based on an open-label, phase 3 trial (NCT02737501) that enrolled 275 patients with locally a...
Continue reading

Nivolumab/Ipilimumab Approved for Metastatic Non-Small Cell Lung Cancer

For patients with advanced non-small cell lung cancer (NSCLC) that test positive for programmed death-ligand 1 (PD-L1), the FDA just approved an effective treatment: nivolumab (Opdivo ®, Bristol Myers Squibb) plus ipilimumab (Yervoy®, Bristol Myers Squibb). A companion diagnostic, PD-L1 IHC 28.8 pharmDx (Agilent Technologies, Inc.), was also FDA approved for selecting patients with NSCLC for treatment with nivolumab/ipilimumab.Previously approved to treat advanced kidney cancer, advanced liver c...
Continue reading

Olaparib/Bevacizumab Combination Approved as Maintenance Therapy: Ovarian, Fallopian Tube, Peritoneal Cancer

Olaparib (Lynparza®, AstraZeneca Pharmaceuticals, LP), in combination with bevacizumab (Avastsin®, Genentech), is now FDA approved as first-line maintenance treatment for adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who have had a complete or partial response to first-line platinum-based chemotherapy. Patients must also have cancer that is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or ...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.